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ABSTRACT 
 
Background—Atrial fibrillation (AF) is associated with increased incidence of 
cardiovascular disease, and hence, statin therapy is indicated in majority of AF 
patients.    
Methods and results—We analyzed data from the Chinese Atrial Fibrillation Registry 
(CAFR) involving 11496 AF patients from 2011 to 2014. Practice patterns of statin 
therapy and factors associated with statin underuse were analyzed.  
Based on the 2013 ACC/AHA cholesterol management guidelines, statins should be 
recommended for 67.4% (7720/11461) of AF participants in CAFR, but only 43.4% 
(3352/7720) with appropriate indications were taking statins. Statin underuse in AF 
patients was independently associated with male sex, tertiary hospital treatment, 
outpatient attendance, and absence of ‘high risk’ cardiovascular risk factors 
(overweight, diabetes, coronary heart disease, stroke/transient ischemic 
attack/peripheral embolism and hypertension). 
Conclusions—A high proportion of Chinese AF patients had indications for statin 
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therapy. Evidence-based statin prescribing was suboptimal in this population. 
Greater efforts should be made to improve a holistic approach to cardiovascular risk 
management in the Chinese AF population. 
 
 
 
 
Introduction 
Atrial Fibrillation (AF) is the most common cardiac arrhythmia, with 33.5 million 
prevalent and additional 5 million incident AF cases being reported in 2010 
worldwide.[1] AF is consistently associated with a higher risk of morbidity and 
mortality, especially from cardiovascular conditions.[2, 3] In addition, the presence of 
cardiovascular comorbidities and risk factors are not uncommon in AF patients. Due 
to high prevalence of cardiovascular risk factors among AF patients, risk of adverse 
cardiovascular outcomes is also substantially higher in this group of patients.[4-6]  
 
In the Action in Diabetes and Vascular Disease: preterAx and diamicroN-MR 
Controlled Evaluation (ADVANCE) study, for example, AF was found to be associated 
with substantially increased risk of death and cardiovascular events in patients with 
type 2 diabetes.[7] In the Reasons for Geographic and Racial Differences in Stroke 
(REGARDS) study, AF patients had almost 2-fold higher risk of myocardial infarction 
[hazard ratio 1.96, 95% confidence interval (CI), 1.52-2.52] after adjusting 
confounding factors.[8] More recently, incident AF was found to be associated with 
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increased risk of sudden cardiac death (SCD) and non-SCD in the general 
population.[9] Despite this high cardiovascular risk, management of risk factors is 
sometimes neglected in practice, given that stroke prevention is the most feared 
complication of AF and much focus is directed on oral anticoagulation therapy.  
 
Statin therapy can substantially reduce the risk of cardiovascular disease.[10] Given 
their high cardiovascular risk, treatment with statins may bring larger absolute risk 
reduction for AF patients. As the public health burden of AF in China is increasing, 
insights into the pattern of statin usage in AF patients will provide important 
information for future healthcare quality improvement.  
 
The ongoing Chinese Atrial Fibrillation Registry (CAFR) recruited AF patients from 31 
hospitals located in urban and semi-urban areas of Beijing. In this report from CAFR, 
we studied the use of statin therapy in this population and explored factors 
associated with statin underuse in clinical practice, amongst Chinese AF patients.  
 
 
Methods 
Study design and participants 
The Chinese Atrial Fibrillation Registry (CAFR) is a prospective, multicenter, 
hospital-based, ongoing registry study of patients diagnosed with AF in Beijing, China. 
The majority of tertiary and nontertiary hospitals providing a clinical service of AF 
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management in Beijing participated in this registry study. Data collected between 
August 2011 and July 2014 from 31 hospitals were used for analyses.  
 
Trained personnel including doctors from tertiary and nontertiary hospitals enrolled 
unselected eligible AF outpatients and inpatients from their daily practices. 
Abstracted data were submitted to the CAFR registry website. Eligible patients were 
those aged ≥ 18 years, with AF documented via either electrocardiogram (ECG) or 
Holter within the past 6 months. AF was diagnosed by local investigator via the 
baseline 12-lead ECGs or Holter recordings. Written informed consent was obtained 
from each patient. Those patients with transient and reversible AF, suffering from 
other diseases with a life expectancy < 1 year, diagnosed with rheumatic mitral 
stenosis or having mitral valve prostheses were excluded. 
 
Data collection 
Patients’ characteristics information, including socio-demographic data (age, gender, 
level of education, and medical insurance status), medical history [history of 
congestive heart failure, hypertension, diabetes, hyperlipidemia, prior 
stroke/transient ischemic attack (TIA)/peripheral thromboembolism, established 
coronary heart disease (any history of myocardial infarction, percutaneous coronary 
intervention or coronary artery bypass graft surgery), hyperlipidemia, prior bleeding], 
cardiovascular risk factors (smoking, alcohol consumption and body mass index), 
results of physical examinations, results of the latest laboratory tests, including liver 
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and renal function, blood glucose and cholesterol levels, tested within 1 year or at 
the time of enrollment, results of electrocardiogram and echocardiogram, and 
medical therapies received were collected.  
 
Definition of population with indications for statins 
According to the 2013 American College of Cardiology/American Heart Association 
(ACC/AHA) guideline, statins use was recommended for four subgroups of patients: 
adults with atherosclerotic cardiovascular disease, adults with LDL 
cholesterol>190mg/dL, adults 40-79 years old with LDL cholesterol 70-189 mg/dL 
and diabetes, and adults with a 10-year predicted risk for atherosclerotic 
cardiovascular disease (ASCVD) ≥5%.[10]  
 
In this study, ASCVD was defined as positive history of acute coronary syndromes, 
myocardial infarction, stable or unstable angina, coronary or other arterial 
revascularization, stroke/TIA, or peripheral arterial disease presumed to be of 
atherosclerotic origin. 10-year risk of ASCVD was predicted with a simplified point 
score model as recommended by Chinese guidelines.[11, 12] The algorithm used in 
this study is provided in the appendix Figure 1.  
 
Statistical analysis 
Categorical variables were shown as n(%), whereas continuous variables are shown 
as mean (standard deviation, SD). Continuous variables were compared using either 
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the unpaired T-test or the Mann-Whitney U test, whereas categorical variables were 
compared using the Chi-square test. For the analysis of factors associated with 
non-use of statins in AF patients who have indication(s), a univariate logistic 
regression was first conducted by using each baseline variable as a covariate. A 
logistic regression model was then applied to include all the significant covariates 
identified in the univariate analysis. A stepdown method was used to determine the 
final model of the logistic regression. To investigate whether the rate of statin usage 
differed significantly among hospitals after considering the differences in patients’ 
characteristics, we also fitted a generalized linear mixed model with hospital included 
as a random effect and tested whether the variance for the random effect was 
significantly different from zero. The results were shown in appendix. A P value <0.05 
was considered statistically significant. All analyses were conducted using SAS 
software, version 9.2. 
 
Ethical approval 
The CAFR was reviewed and approved by the Ethics committee of Beijing Anzhen 
Hospital. 
 
 
Results 
We included 11496 patients with AF (average age 65.8 ± 12.0 years, 40.4% female), 
where the prevalence of patients with history of hypertension, congestive heart 
failure, diabetes, stroke/TIA/peripheral embolism, established coronary heart 
diseases and hyperlipidemia were 66.1%, 18.9%, 24.5%, 17.0%, 17.8% and 27.0%, 
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respectively (Table 1). More than half (52.9%) of patients had paroxysmal AF, 38.3% 
with persistent AF, and the rest with newly diagnosed AF. The majority of enrolled 
patients (92.0%) were totally or partially covered by medical insurance. Compared to 
participants enrolled from tertiary hospitals, those enrolled from nontertiary 
hospitals were older, more likely to have comorbidities, and more likely to be 
smokers, had lower education status and permanent AF (Table 1). 
 
Statin usage among those with indications 
Overall, 67.4% (7720/11461) of AF patients had indication(s) for statin therapy while 
only 43.4% (3352/7720) patients with indication(s) were taking statin. Usage of stain 
varied among patients with different indications (Table 2): 57.8% (2022/3500) of 
those patients with a history of ASCVD were taking statin.  
 
For those with LDL-C≥190 mg/dL, 58.1% (36/62) patients were taking statin. In 
contrast, only 37.6% (303/807) of patients aged 40-79 years old with diabetes and 
LDL cholesterol=70-189 mg/dL and 29.6% (991/3351) of patients who had predicted 
10-year-ASCVD risk≥5% were taking statin. Of note, 20.6% (771/3741) of AF patients 
with no guideline recommended indications for statin use were taking it. Among 
patients with statin indications, the proportion of statin usage varied from 32% to 74% 
in tertiary hospitals and from 33% to 75% in nontertiary hospitals (Figure 1).  
 
Factors associated with statin usage in AF patients 
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After adjusting covariates that may impact the use of statins, underuse in AF patients 
were found to be independently associated with male sex [odds ratio (OR) 1.15, 
95%CI 1.03-1.29] and tertiary hospital treatment (OR 1.99, 95%CI 1.70-2.31), while 
inpatients treatment (OR 0.70, 95%CI 0.63-0.79), BMI≥28 (OR 0.80, 95%CI 0.70-0.91) 
and comorbidities including history of diabetes, CHD, stroke/TIA/peripheral 
embolism and hypertension were associated with higher likelihood of statin use. ORs 
of statin underuse among patients with these comorbidities were 0.74 (95%CI 
0.66-0.83), 0.26 (95%CI 0.23-0.30), 0.59 (95%CI 0.52-0.67) and 0.60 (95%CI 0.53-0.69) 
respectively. (Table 3) 
 
In subgroups of patients treated in tertiary and nontertiary hospitals, factors 
associated with non-use of statins were also analyzed by the proc glimmix model 
which included hospital type as a random effect, and showed consistent results 
(intercept P among tertiary hospitals: 0.3396, non-tertiary hospital: 0.2888).  [see 
Appendix Table 1-2] 
 
 
Discussion 
In this contemporary large registry study of statin therapy use in patients with AF we 
found that statin was greatly underused in AF patients, especially in those with a 
10-year predicted risk for ASCVD≥5% and those aged 40-79 years old with LDL 
cholesterol 70-189 mg/dL and diabetes. Conversely a substantial proportion of AF 
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patients with no indication for statins were prescribed these drugs. 
 
Several large cohort studies have noticed increased risk of adverse cardiovascular 
outcomes beyond stroke in AF patients, that is, cardiovascular events including heart 
failure, myocardial infarction, etc.[6, 13, 14] However, the importance of preventing 
cardiovascular events is perhaps under-emphasized in current practice. ASCVD is not 
an uncommon comorbidity in AF patients.[15-17] On the other hand, AF patients 
already receiving anticoagulation therapy still suffer from a relative high risk of 
ASCVD events.[14, 18] Given the increased risk of AF-associated mortality and 
cardiovascular complications, especially the bidirectional relationship between AF 
and ASCVD,[8, 19] a comprehensive and holistic management approach of all 
cardiovascular risk factors in AF patients is of vital importance. 
 
Much of the focus of AF management is directed towards stroke prevention with 
antithrombotic therapy, as well as rate or rhythm control. Less attention is paid to 
the importance of cardiovascular risk factor modification. Indeed, suboptimal statin 
usage was observed in our study, whereby over 65% of Chinese AF patients had 
statin indications while less than half of them were prescribed statin. Although the 
underuse of evidence-based cardiac prevention therapy has been noticed in patients 
with coronary heart disease [20-22] and initiatives have been launched to improve 
this, suboptimal treatment among patients with AF has not yet got enough attention. 
Aside from optimal statin usage, optimal management of traditional risk factors like 
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hypertension and diabetes, management of obesity and overweight, leading healthy 
lifestyle are of equal importance in reducing cardiovascular risk and AF management. 
[23] However, it is reported that only a minority of patients received indicated 
therapies for their comorbidities and nearly half patients hadn’t have their blood 
pressure controlled.[24] Importantly, AF patients whose predicted 10-year-ASCVD 
risk ≥5% in our study were least likely to receive any statin, reflecting the practice 
pattern of statin use which is more likely to be based on single disease rather than 
considering the complexity of all comorbidities and risk factors. Over-prescribing was 
evident in more than 20% of AF patients without indication for statins.  
 
Interestingly, we observed a statin prescription “paradox” in different level hospitals. 
Patients treated in tertiary hospitals were less likely to receive guideline-indicated 
statins. There are several possible underlying reasons for this prescription paradox.  
First, doctors in tertiary hospitals are busier and looking after more patients so that 
they had more limited time to consider the importance of statin therapy. Second, 
doctors in tertiary hospitals focused more on anticoagulation therapy and even more 
invasive and expensive interventions such as ablation therapy, whilst statin therapy is 
ignored. After adjusting for covariates, we found outpatients and male patients to be 
less likely to be prescribed statin. This is in line with our hypothesis that doctors in 
the outpatients department were less likely to have enough time to communicate 
with patients about the necessity of taking statins. Moreover, statin underuse was 
associated with fewer comorbid conditions and less overweight, which again 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 13 
suggests that doctors are likely to ignore statin therapy in those patients with 
multiple moderate increased risk factors while great increased global cardiovascular 
risk. We didn’t find medical insurance coverage was a risk factor for stain under 
prescription in this study. One possible explanation is that majority of Beijing 
residents are covered by “medical insurance for urban residents” or “medical 
insurance for urban employees”. Out-of-pocket expense is about 30% of the medical 
fee for out-of-hospital medication. For rural residents, although only 50% of 
in-hospital cost can be reimbursed by “new rural cooperative medical care”, the costs 
of statins are not unaffordable as generic statins are less expensive.  
 
Limitations 
The study population was composed of AF patients recruited from hospitals in Beijing, 
China’s capital, and might not fully represent the whole AF population in China. Since 
majority of the recruiting sites were high-level medical centers located in urban areas, 
we can assume that statin use may be poorer in other areas of the country, especially 
in rural areas. The importance of statin therapy and treat the AF patient as a whole 
person rather than a single medical problem should be more emphasized in related 
guidelines. Reasons for not prescribing statin in AF population were not collected and 
thus detailed analysis cannot be provided, including the proportion with drug 
intolerance. The majority of our patients were covered by health insurance and thus, 
drug costs are not likely to account for the substantial proportion with non-use of 
statins.  
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Conclusions 
A high proportion of Chinese AF patients had indications for statin therapy. 
Evidence-based statin prescribing was suboptimal in this population. Greater efforts 
should be made to improve a holistic approach to cardiovascular risk management in 
the Chinese AF population. 
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Figure Legends 
Figure 1．Statin use in different hospitals amongst AF patients with indications. 
Inclusion of at least 50 patients from each participating hospital was sought. 
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Table 1.  Baseline characteristics of the patients. 
Characteristics Tertiary  
(N=10029) 
Nontertiary  
 (N=1467) 
Overall  
(N=11496) 
Age (mean±SD) 65.0±12.0 70.8±10.0 65.8±12.0 
Gender, male   6050/10029 (60.3) 796/1467 (54.3) 6846/11496 
(59.6) 
Congestive heart 
failure  
1456/10029 (14.5) 718/1467 (48.9) 2174/11496 
(18.9) 
Hypertension  6432/10018 (64.2) 1157/1467 
(78.9) 
7589/11485 
(66.1) 
Diabetes   2349/10029 (23.4) 464/1467 (31.6) 2813/11496 
(24.5) 
Prior 
Stroke/TIA/Peripher
al embolism  
1597/10028 (15.9) 356/1467 (24.3) 1953/11495 
(17.0) 
Prior bleeding  472/10028 (4.7) 57/1467 (3.9) 529/11495 (4.6) 
Hyperlipidemia  2620/10002 (26.2) 471/1459 (32.3) 3091/11461 
(27.0) 
Established CHD*   1680/10028 (16.8) 366/1466 (25.0) 2046/11494 
(17.8) 
Smoking      
  Current  1606/9968 (16.1) 242/1461 (16.6) 1848/11429 
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(16.2) 
  Former  1604/9968 (16.1) 332/1461 (22.7) 1936/11429 
(16.9) 
  None  6758/9968 (67.8) 887/1461 (60.7) 7645/11429 
(66.9) 
Alcohol    
  Current  1901/9958 (19.1) 235/1461 (16.1) 2136/11419 
(18.7) 
  Former  1177/9958 (11.8) 205/1461 (14.0) 1382/11419 
(12.1) 
  None  6880/9958 (69.1) 1021/1461 
(69.9) 
7901/11419 
(69.2) 
BMI (mean±SD)  25.4±3.7 25.3±3.8 25.4±3.7 
Type of AF     
  First time of 
diagnose 
691/10029 (6.9) 323/1467 (22.0) 1014/11496 
(8.8) 
  Paroxysmal  5620/10029 (56.0) 463/1467 (31.6) 6083/11496 
(52.9) 
  Persistent 3718/10029 (37.1) 681/1467 (46.4) 4399/11496 
(38.3) 
Completed higher 
education  
3032/8281 (36.6) 117/1450 (8.1) 3149/9731 
(32.4) 
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Types of health 
insurance  
   
    None  825/10029 (8.2) 93/1467 (6.3) 918/11496 (8.0) 
    Partially  7906/10029 (78.8) 1284/1467 
(87.5) 
9190/11496 
(79.9) 
    100%  1298/10029 (12.9) 90/1467 (6.1) 1388/11496 
(12.1) 
Type of healthcare    
    Outpatients  4923/10029 (49.1) 377/1467 (25.7) 5300/11496 
(46.1) 
    Inpatients 5106/10029 (50.9) 1090/1467 
(74.3) 
6196/11496 
(53.9) 
Values are n/N (%), unless otherwise indicated. 
BMI indicates body mass index; TIA, transient ischemic attack; CHD, coronary heart 
disease;  
* Established Coronary heart disease includes history of myocardial infarction, history 
of percutaneous coronary intervention and history of coronary artery bypass grafting 
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Table 2.  Statin use and prevalence of indications for statin use among CAFR Study 
participants  
Participants Subgroups 
Tertiary Nontertiary 
P With 
indication 
Taking 
statin 
With 
indication 
Taking 
statin 
History of ASCVD* 2881 1619/2881 
(56.2%) 
619 403/619 
(65.1%) 
<0.001 
LDL-C ≥190 mg/dL 56 32/56 
(57.1%) 
6 4/6 
(66.7%) 
0.653 
Diabetes, LDL-C 70-189 
mg/dL, 40-75y 
697 241/697 
(34.6%) 
110 62/110 
(56.4%) 
<0.001 
10-year-ASCVD risk≥5% 2895 777/2895 
(26.8%) 
456 214/456 
(46.9%) 
<0.001 
Any indication for statin 
therapy 
6529 2669/6529 
(40.9%) 
1191 683/1191 
(57.4%) 
<0.001 
No indication for statin 
therapy 
3469 660/3469 
(19.0%) 
272 111/272 
(40.8%) 
<0.001 
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*  History of atherosclerotic cardiovascular disease (ASCVD) includes acute coronary 
syndromes, history of MI, stable or unstable angina, coronary or other arterial 
revascularization, stroke, TIA, or peripheral arterial disease presumed to be of 
atherosclerotic origin.  
LDL-C indicate low-density lipoprotein cholesterol. 
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Table 3.  Factors associated with no statin use in AF patients who have indications  
Characteristics n/N(%) Crude OR (95%CI)  Adjusted OR (95%CI)  
Age 
 
 
 
    <75 
2952/5161 
(57.2) 
1.00 (reference) - 
    ≥75 
1416/2570 
(55.1) 
0.92 (0.84,1.01) - 
Gender 
 
  
    Female 
2678/4578 
(58.5) 
1.00 (reference) 1.00 (reference) 
    Male 
1690/3159 
(53.5) 
1.23 (1.12,1.35) 1.15 (1.03,1.29) 
Education 
 
 
 
    Higher education 
1193/1949 
(61.2) 
1.00 (reference) - 
    Lower education 
2529/4607 
(54.9) 
0.77 (0.69,0.89) - 
Hospital level 
 
  
    Nontertiary 508/1191 (42.6) 1.00 (reference) 1.00 (reference) 
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Characteristics n/N(%) Crude OR (95%CI)  Adjusted OR (95%CI)  
    Tertiary 
3860/6529 
(59.1) 
1.94 (1.72,2.20) 1.99 (1.70,2.31) 
Diabetes 
 
  
    No 
3091/5178 
(59.7) 
1.00 (reference) 1.00 (reference) 
    Yes 
1277/2559 
(49.9) 
0.67 (0.61,0.74) 0.74 (0.66,0.83) 
BMI 
 
  
    BMI < 28 
3107/5348 
(58.1) 
1.00 (reference) 1.00 (reference) 
    BMI ≥ 28 781/1491 (52.4) 0.79 (0.71,0.89) 0.80 (0.70,0.91) 
Established CHD 
 
  
    No 
3713/5685 
(65.3) 
1.00 (reference) 1.00 (reference) 
    Yes 654/2044 (32.0) 0.25 (0.22,0.28) 0.26 (0.23,0.30) 
Stroke/TIA/Peripheral 
embolism  
  
    No 
3406/5783 
(58.9) 
1.00 (reference) 1.00 (reference) 
    Yes 962/1951 (49.3) 0.68 (0.61,0.75) 0.59 (0.52,0.67) 
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Characteristics n/N(%) Crude OR (95%CI)  Adjusted OR (95%CI)  
Hypertension 
 
  
    No 
1254/1855 
(67.6) 
1.00 (reference) 1.00 (reference) 
    Yes 
3107/5873 
(52.9) 
0.54 (0.48,0.60) 0.60 (0.53,0.69) 
Congestive heart failure 
 
  
    No 
3551/5968 
(59.5) 
1.00 (reference) - 
    Yes 817/1765 (46.3) 0.59 (0.53,0.65) - 
Health insurance 
 
 
 
    100% covered 608/1042 (58.3) 1.00 (reference) - 
    Partially covered 
3434/6154 
(55.8) 
0.91 (0.80,1.04) - 
    None 326/541 (60.3) 1.09 (0.89,1.34)  - 
Smoking 
 
  
    No 
3672/6511 
(56.4) 
1.00 (reference) - 
    Yes 678/1181 (57.4) 1.04 (0.92,1.18) - 
Alcohol 
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Characteristics n/N(%) Crude OR (95%CI)  Adjusted OR (95%CI)  
    No 
3562/6384 
(55.8) 
1.00 (reference) - 
    Yes 782/1299 (60.2) 1.21 (1.07,1.36) - 
Form of treatment 
 
  
    Outpatients 
2225/3532 
(63.0) 
1.00 (reference) 1.00 (reference) 
    Inpatients 
2143/4202 
(51.0) 
0.61 (0.56,0.67) 0.70 (0.63,0.79) 
 
BMI indicates body mass index; TIA, transient ischemic attack; CHD, coronary heart 
disease. 
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